This article is more than 5 years old. Information may no longer be current.

New research center will accelerate the development of new antibiotics

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Researchers at the University of Liverpool plan to establish the Center for Antimicrobial Pharmacodynamics, or CAP, a research center created to help rapidly develop new antibiotics to treat and manage infections caused by resistant pathogens, according to a press release.

“Characterizing the preclinical and clinical pharmacokinetics and pharmacodynamics of anti-infective drugs is a relatively recent and mandatory regulatory requirement, which has created a bottleneck for [antimicrobial resistance] project progression because there is a lack of global skills and capacity to meet demand,” William Hope, BMBS, FRACP, FRCPA, PhD, professor of therapeutics and infectious diseases at the University of Liverpool who will lead the new Center, said in the release. “The CAP will build on Liverpool’s existing strength in antimicrobial pharmacodynamics and therapeutics research to give scientists access to the skills and equipment they need to advance the development of new antibiotics.”

In response to the growing antimicrobial resistant problem in the U.K. and worldwide, the CAP will provide researchers and companies with access to pharmacodynamics research expertise, facilities and training, which will lead to the development of new antimicrobial drugs. The center will offer a local resource for roughly 20 U.K. and 90 global antimicrobial resistance companies, aligning with antibiotic resistance accelerators in the U.S. and Europe. The facility will focus on teaching and training for all aspects of antimicrobial pharmacodynamics. Some highlights of the CAP include advanced in vitro and in vivo models of infection; preclinical imaging facilities; mathematical modelling skills; and advanced pharmacokinetics and pharmacodynamics.

Innovate U.K. awarded the University of Liverpool more than $700,000 to develop the CAP in partnership with Liverpool School of Tropical Medicine (LSTM) and North Bristol NHS Trust. Separately, the University will also invest in new senior academic posts. The CAP is the first project announced as part of a collaboration between University of Liverpool and LSTM’s Center of Excellence in Infectious Disease Research (CEIDR).

Disclosures: The project received funding from Innovative U.K., LSTM, North Bristol NHS Trust and University of Liverpool.